The Double-Faced t(12;21) in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Patients: Seven Years Experience at a Tertiary Center
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.10.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Eman O Rasekh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Translocation, Genetic, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 12. Die Arbeit nennt 53 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: ETV6:RUNX1 has a good prognosis in pediatric acute lymphoblastic leukemia (ALL). However, it shows a controversial prognostic pattern due to the increased risk of late relapses. We aimed to analyze the clinico-laboratory features and treatment outcomes of patients with ETV6::RUNX1. METHODS: This study involved newly diagnosed precursor B-ALL pediatric patients who had the ETV6::RUNX1 fusion gene between January-2016 and December-2022, in the National Cancer Institute (NCI), Cairo University. RESULTS: Out of 645, 111 (17.2%) tested positive for ETV6::RUNX1. The mean age was 5.2 years (SD ± 2.9). Conventional cytogenetic analysis revealed that 54.2% (39/71) had concurrent chromosomal aberrations. Younger age (< 10 years) and initial leukocyte count ≤ 50,000/µl were associated with better remission outcomes (P < .001 and P = .03, respectively). Overall survival (OS) was significantly affected by the remission status on day 15 (P = .001) and disease risk (P = .006). Additionally, disease-free survival (DFS) was negatively impacted by splenomegaly (P = .042), the immunophenotyping of c-ALL (P = .01), and the presence of aberrant myeloid markers (P = .001). Twelve patients (10.8%) experienced relapses. The 5-year estimated cumulative incidence of relapse (CIR) was significantly lower for hypodiploidy and high hyperdiploidy when compared to the modal chromosomal number (MCN) of 47 to 50 chromosomes (0%, 0% vs. 21%, P < .001). Multivariate analysis identified the initial platelet count < 40 × 10³/mL as an adverse independent prognostic factor impacting the OS. CONCLUSIONS: The treatment protocols need to be tailored based on further refine the stratification of ETV6::RUNX1 patients. Platelet count is an adverse independent prognostic factor. Splenomegaly and aberrant CD33 expression are associated with shorter DFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Electronic address: d_mostafaselim@cu.edu.eg.
- Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Zitieren
APA
Rasekh, E. O., Selim, M., Arafah, O., Gamal, H., & Ashry, M. S. E. (2025). The Double-Faced t(12;21) in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Patients: Seven Years Experience at a Tertiary Center. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.023
Vancouver
Rasekh EO, Selim M, Arafah O, Gamal H, Ashry MSE. The Double-Faced t(12;21) in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Patients: Seven Years Experience at a Tertiary Center. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.10.023
BibTeX
@article{Rasekh2025,
author = {Rasekh, Eman O and Selim, Mustafa and Arafah, Omar and Gamal, Hend and Ashry, Mona S El},
title = {The Double-Faced t(12;21) in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Patients: Seven Years Experience at a Tertiary Center},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.10.023}
}
EUVIMED